omnic® software package (version 7.3 Search Results


90
Chemie GmbH naxan aal naphthalene sulfonate
Naxan Aal Naphthalene Sulfonate, supplied by Chemie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/naxan+aal+naphthalene+sulfonate/us07588645-256-23-58
Average 90 stars, based on 1 article reviews
naxan aal naphthalene sulfonate - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Polytek Development Corp platsil 73-40
Platsil 73 40, supplied by Polytek Development Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/platsil73+25/pmc06170766-91-32-29
Average 90 stars, based on 1 article reviews
platsil 73-40 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Hamamatsu hamamatsu r5509-73 photomultiplier
Hamamatsu R5509 73 Photomultiplier, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/photomultiplier+tube+hamamatsu+r928/10__1063_slash_1__4858393-50-29-28
Average 90 stars, based on 1 article reviews
hamamatsu r5509-73 photomultiplier - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Sony sony xc-73
Sony Xc 73, supplied by Sony, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/ccd+camera/pmc10025931-31-4-3
Average 90 stars, based on 1 article reviews
sony xc-73 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

95
HORIBA Ltd laqua f 73 manufactured by
Laqua F 73 Manufactured By, supplied by HORIBA Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/LAQUA+F-73/us12247299-468-50-54
Average 95 stars, based on 1 article reviews
laqua f 73 manufactured by - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

90
Hamamatsu r5509-73 pmt c9940-02 cooler
R5509 73 Pmt C9940 02 Cooler, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/c9940+22+detector/10__1039_slash_c9sc00220k-190-38-37
Average 90 stars, based on 1 article reviews
r5509-73 pmt c9940-02 cooler - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Promega pgl4.73
Pgl4.73, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/pgl3+basic/pmc02916059-384-22-23
Average 90 stars, based on 1 article reviews
pgl4.73 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Strahl Pitsch Inc ozokerite wax pastilles sp 1021 p
Ozokerite Wax Pastilles Sp 1021 P, supplied by Strahl Pitsch Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/ozokerite+wax+pastilles+sp+1021+p/us10154954-0-83-93
Average 90 stars, based on 1 article reviews
ozokerite wax pastilles sp 1021 p - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Promega pgl4.13 fluc reporter plasmid
Pgl4.13 Fluc Reporter Plasmid, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/firefly+luciferase+vector++pgl4+13++luc2+sv40/pmc03763458-131-13-14
Average 90 stars, based on 1 article reviews
pgl4.13 fluc reporter plasmid - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BOC Sciences mcb placebo
BOC, boceprevir; <t>MCB,</t> mericitabine; <t>P/R,</t> <t>peginterferon</t> alfa-2a + ribavirin.
Mcb Placebo, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/Monochlorobimane/pmc04713467-111-9-11
Average 90 stars, based on 1 article reviews
mcb placebo - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Destiny Pharma xf-73
BOC, boceprevir; <t>MCB,</t> mericitabine; <t>P/R,</t> <t>peginterferon</t> alfa-2a + ribavirin.
Xf 73, supplied by Destiny Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/xf+73/pmc08689412-33-0-21
Average 90 stars, based on 1 article reviews
xf-73 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
COMSOL Inc comsol multiphysics software
BOC, boceprevir; <t>MCB,</t> mericitabine; <t>P/R,</t> <t>peginterferon</t> alfa-2a + ribavirin.
Comsol Multiphysics Software, supplied by COMSOL Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/omnic%C2%AE+software+package+(version+7%2E3/comsol+multiphysics/pm39418182__ac4c05334_si_001-1-60-71
Average 90 stars, based on 1 article reviews
comsol multiphysics software - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin.

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin.

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques:

MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques:

BOC, boceprevir 800 mg TID (at recommended intervals of 7–9 hours); MCB, mericitabine 1000 mg BID; P/R, peginterferon alfa-2a 180 μg once/week + ribavirin 1000 mg/day (<75 kg) or 1200 mg/day (≥75 kg); PBO, placebo; TVR, telaprevir 750 mg TID (at recommended intervals of 7–9 hours). Control Arms C in DYNAMO 1 and D in DYNAMO 2 were closed due to futility while the studies were ongoing (27 July 2012 in DYNAMO 1 and 10 July 2012 in DYNAMO 2), after which patients in these groups were given the option to receive mericitabine for a maximum duration of 24 weeks. MCB was added to the regimen for 5 patients in Arm C in DYNAMO 1 and to the regimen for 9 patients in Arm D in DYNAMO 2 at various time points and for various durations.

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: BOC, boceprevir 800 mg TID (at recommended intervals of 7–9 hours); MCB, mericitabine 1000 mg BID; P/R, peginterferon alfa-2a 180 μg once/week + ribavirin 1000 mg/day (<75 kg) or 1200 mg/day (≥75 kg); PBO, placebo; TVR, telaprevir 750 mg TID (at recommended intervals of 7–9 hours). Control Arms C in DYNAMO 1 and D in DYNAMO 2 were closed due to futility while the studies were ongoing (27 July 2012 in DYNAMO 1 and 10 July 2012 in DYNAMO 2), after which patients in these groups were given the option to receive mericitabine for a maximum duration of 24 weeks. MCB was added to the regimen for 5 patients in Arm C in DYNAMO 1 and to the regimen for 9 patients in Arm D in DYNAMO 2 at various time points and for various durations.

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques:

Baseline characteristics (all randomized patients). BOC, boceprevir;  MCB,  mericitabine; P/R,  peginterferon  alfa-2a/ribavirin; TVR, telaprevir

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: Baseline characteristics (all randomized patients). BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a/ribavirin; TVR, telaprevir

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques:

BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques:

Virological response at end of treatment and at week 4, 12 and 24 of follow-up (all treated patients) and relapse at week 4, 12 and 24 of follow-up. BOC, boceprevir; CI, 95% confidence interval;  MCB,  mericitabine; P/R,  peginterferon  alfa-2a/ribavirin; TVR, telaprevir

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: Virological response at end of treatment and at week 4, 12 and 24 of follow-up (all treated patients) and relapse at week 4, 12 and 24 of follow-up. BOC, boceprevir; CI, 95% confidence interval; MCB, mericitabine; P/R, peginterferon alfa-2a/ribavirin; TVR, telaprevir

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques:

Adverse events and laboratory abnormalities. ALT, alanine transaminase; BOC, boceprevir;  MCB,  mericitabine; P/R,  peginterferon  alfa-2a/ribavirin; TVR, telaprevir; ULN, upper limit of normal

Journal: PLoS ONE

Article Title: Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

doi: 10.1371/journal.pone.0145409

Figure Lengend Snippet: Adverse events and laboratory abnormalities. ALT, alanine transaminase; BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a/ribavirin; TVR, telaprevir; ULN, upper limit of normal

Article Snippet: Patients randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin, followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks.

Techniques: